Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation

Navigating SG&A Expenses: A Tale of Two Biotech Firms

In the competitive world of biotechnology, managing costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Protagonist Therapeutics, Inc. and Geron Corporation from 2014 to 2023. Over this period, Geron Corporation's SG&A expenses surged by over 300%, peaking in 2023. In contrast, Protagonist Therapeutics, Inc. saw a more modest increase of approximately 80% during the same timeframe.

Key Insights

• Geron Corporation: From 2014 to 2023, Geron Corporation's SG&A expenses grew significantly, reflecting strategic investments in operations and marketing.
• Protagonist Therapeutics, Inc.: Despite a slower growth rate, Protagonist Therapeutics, Inc. maintained a steady increase in SG&A expenses, indicating a cautious yet progressive approach.

Understanding these trends provides valuable insights into how these companies allocate resources to drive growth and innovation.